A dexamethasone and lidocaine composite liposome nanomedicine, a preparation method and application thereof
By encapsulating dexamethasone and lidocaine in a composite liposome nanomedicine system, the problem of pharmacokinetic mismatch was solved, achieving spatiotemporal synergy between rapid analgesia and long-lasting anti-inflammation, reducing the risk of systemic toxicity, and making it suitable for local anti-inflammatory analgesia and nerve block scenarios.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GUANGZHOU INSTITUTE OF RESPIRATORY HEALTH (GUANGZHOU INSTITUTE OF RESPIRATORY DISEASES)
- Filing Date
- 2026-06-08
- Publication Date
- 2026-07-17
AI Technical Summary
In existing technologies, the pharmacokinetics of dexamethasone and lidocaine are mismatched, resulting in uncoordinated drug release after local administration and the risk of systemic side effects. Traditional formulation processes are cumbersome and it is difficult to achieve long-term local retention.
A composite liposome nanomedicine system was used, in which lidocaine was encapsulated in a lipid bilayer composed of phospholipids, cholesterol and PEGylated lipids, and dexamethasone was encapsulated in the inner aqueous phase, with the particle size controlled in the range of 50-500 nm, to achieve time-sequential synergistic release and long-term retention of the drug.
It achieves efficient co-loading of dexamethasone and lidocaine, and achieves spatiotemporal synergy of rapid analgesia and long-lasting anti-inflammatory effects, significantly prolonging the duration of drug efficacy and reducing the risk of systemic toxicity. It is suitable for local anti-inflammatory analgesia, nerve block and intra-articular injection scenarios.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3